Directions: Identify what is required to complete the following figures.

1.

313 Patients assessed for eligibility

88 Randomized

44 Randomized to receive early surgical treatment
   41 Received treatment as randomized
   3 Did not receive treatment as randomized
   2 Underwent endoscopy
   1 Did not receive intervention

44 Randomized to receive the endoscopy-first approach (step-up practice)
   44 Underwent medical management
   39 Underwent endoscopy
   13 Underwent surgery

1 Lost to follow-up

44 Included in the primary analysis

33 Included in the per-protocol analysis
   11 Excluded
   7 Time between randomization and surgery >6 wk
   3 No surgery
   1 Different type of surgery

2 Lost to follow-up

44 Included in the primary analysis

32 Included in the per-protocol analysis
   12 Excluded
   4 No ESWL despite stones >7 mm
   2 No progressive stenting despite stricture
   1 Wrong inclusion (pancreatic carcinoma)
   1 No endoscopy
   1 No endoscopy and surgery
   1 Too long endoscopy (>1 y stenting)
   1 Endoscopy in other center
   1 No surgery
   1 Surgery in other center
2. Costs in the year prior to amputation, price-adjusted Medicare cost in US$

Proportion of patients undergoing revascularization

3. Maternal prepregnancy BMI category

Least square mean of child BMI z score

Floate quartile
- Q2–Q4
- Q1

18.5–24.9 25–29.9 ≥30
4. 

![Graph showing pleurodesis failure over time for different interventions.](image)

Talc slurry vs. Talc poudrage

5. 

<table>
<thead>
<tr>
<th>Source</th>
<th>Follow-up, y</th>
<th>Intervention</th>
<th>Control</th>
<th>Peto OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chichester, 2007</td>
<td>15</td>
<td>47/2995 (1.6)</td>
<td>54/3045 (1.8)</td>
<td>0.88 (0.66–1.11)</td>
</tr>
<tr>
<td>Mars, 2012</td>
<td>13.1</td>
<td>224/33483 (0.7)</td>
<td>341/33887 (1.1)</td>
<td>0.59 (0.50–0.70)</td>
</tr>
<tr>
<td>Viborg, 2010</td>
<td>13</td>
<td>19/6333 (0.3)</td>
<td>55/6303 (0.9)</td>
<td>0.37 (0.24–0.59)</td>
</tr>
<tr>
<td>Western Australk, 2016</td>
<td>12.8</td>
<td>30/19249 (0.5)</td>
<td>96/19231 (0.5)</td>
<td>0.92 (0.69–1.22)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rupture</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chichester, 2007</td>
<td>15</td>
<td>54/1995 (1.8)</td>
<td>63/3045 (2.1)</td>
<td>0.87 (0.66–1.53)</td>
</tr>
<tr>
<td>Mars, 2012</td>
<td>13.1</td>
<td>273/33483 (0.8)</td>
<td>476/33887 (1.4)</td>
<td>0.58 (0.50–0.67)</td>
</tr>
<tr>
<td>Viborg, 2010</td>
<td>13</td>
<td>16/6333 (0.3)</td>
<td>36/6306 (0.6)</td>
<td>0.46 (0.25–0.79)</td>
</tr>
<tr>
<td>Western Australk, 2016</td>
<td>12.8</td>
<td>72/19249 (0.4)</td>
<td>96/19231 (0.5)</td>
<td>0.73 (0.54–0.98)</td>
</tr>
</tbody>
</table>
Figure Elements Quiz

6. Mean weight change, kg

Follow-up, mo

7. Thyrotropin, mIU/L

Follow-up

No. of participants
Levothyroxine 112 104 93 50
Placebo 139 129 117 58